pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4532 |
Genomic Coordinates | chr20: 57895394 - 57895444 |
Description | Homo sapiens miR-4532 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |
---|---|
Mature miRNA | hsa-miR-4532 |
Sequence | 6| CCCCGGGGAGCCCGGCG |22 |
Evidence | Experimental |
Experiments | Illumina |
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CRISPLD2 | ||||||||||||||||||||
Synonyms | CRISP11, LCRISP2, LGL1 | ||||||||||||||||||||
Description | cysteine rich secretory protein LCCL domain containing 2 | ||||||||||||||||||||
Transcript | NM_031476 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CRISPLD2 | |||||||||||||||||||||
3'UTR of CRISPLD2 (miRNA target sites are highlighted) |
>CRISPLD2|NM_031476|3'UTR 1 ATTTCCAGCACCAGGGGAGAAGGGGCGTCTTCAGGAGGGCTTCGGGGTTTTGCTTTTATTTTTATTTTGTCATTGCGGGG 81 TATATGGAGAGTCAGGAAACTTCCTTTGACTGATGTTCAGTGTCCATCACTTTGTGGCCTGTGGGTGAGGTGACATCTCA 161 TCCCCTCACTGAAGCAACAGCATCCCAAGGTGCTCAGCCGGACTCCCTGGTGCCTGATCCTGCTGGGGCCTGGGGGTCTC 241 CATCTGGACGTCCTCTCTCCTTTAGAGATCTGAGCTGTCTCTTAAAGGGGACAGTTGCCCAAAATGTTCCTTGCTATGTG 321 TTCTTCTGTTGGTGGAGGAAGTTGATTTCAACCTCCCTGCCAAAAGAACAAACCATTTGAAGCTCACAATTGTGAAGCAT 401 TCACGGCGTCGGAAGAGGCCTTTTGAGCAAGCGCCAATGAGTTTCAGGAATGAAGTAGAAGGTAGTTATTTAAAAATAAA 481 AAACACAGTCCGTCCCTACCAATAGAGGAAAATGGTTTTAATGTTTGCTGGTCAGACAGACAAATGGGCTAGAGTAAGAG 561 GGCTGCGGGTATGAGAGACCCCGGCTCCGCCCTGGCACGTGTCCTTGCTGGCGGCCCGCCACAGGCCCCCTTCAATGGCC 641 GCATTCAGGATGGCTCTATACACAGCAGTGCTGGTTTATGTAGAGTTCAGCAGTCACTTCAGAGATGTATCTTGTCTTTG 721 TCAGGCCCTTCGTCTTCATGGCCCACCTGTTTTCTGCCGTGACCTTTGGTCCCATTGAGGACTAAGGATCGGGACCCTTT 801 CTTTACCCCCTACCCGTTGTGGCTCCCACCCTGCCTCGGACTGGTTTACGTGTCCTGGTTCACACCCAGGACTTTTCTTT 881 GCAAGCGAACCTGTTTGAAGCCCAAGTCTTAACTCCTGGTCTCGTAAGGTTCCACTGAGACGAGATGTCTGAGAACAACC 961 AAAGAAGGCCTGCTCTTTGCTGCTTTTAAAAAATGACAATTAAATGTGCAGATTCCCCACGCACCCGATGACCTATTTTT 1041 TCAGCCGTGGGAGGAATGGAGTCTTTGGTACATTCCTCACCGAGGTTAGCAGCTCAGTTTGTGGTTATGAAACCGTCTGT 1121 GGCCTCATGACAGCGAGAGATGGGAATACACTAGAAGGATCTCTTTTCCTGTTTTCGTGAAACGACTCTTGCCAAACGTT 1201 CCCGAGGCGCCAAGGAGTGTAGTACACCCTGGCTGCCATCACTCTATAAAAGTGCTTCATGAGCCCAGACCAAAAGCCCA 1281 CAGTGAAATGAAGTACCCTTTTGTAAATAGCATTTTTTTGCAGAAGGTGAAAATTCCACTCTCTACCACCGGGCCAGCCA 1361 ATAGATCACTTTGGTGAATGCTAGTTTCAAATTTGATTCAAAATATTTCTTAGGTGAAAGAACTAGCAGAAAGTCAAAAA 1441 CTAAGATACTGTAGACTGGACAAGAAATTCTACCTGGGCACCTAGGTGATGCCTTCTTTCTTTGATTGCCTTTCTAATAA 1521 ATGCAGAATCTGAAGGTAAATAGGTTTAAAACAAAACAAAAACCCACCCCTTTAAGGAGTTGGTAAAAAGCAGTTCAACT 1601 CTTAGCTTGACTGAGCTAAAATTCACAGGACTACGTGCTTTGTGCATTGTAGTCTAGTCGTAATTCATAGGTACTGACTC 1681 CTCAGCCCCAAATGTCGGAGAGGAAGAATTCGGTCAGCCTGTCAGGTCGTGAGTCCAGTTACCACCAAACATCTGGGAAA 1761 CTTCTGGGTGCTGGGTGCTCTGCTGCTGGACTTTTGTGGCTGTGTCTGTGTCTGCAAGATAAATTAGATCGCCCTGTGGG 1841 GTTTGCAGAATTAGTGAAGGGTCCAGGACGATCCCAGTGGGCTCGCTTCCAAAGCATCCCACTCAAGGGAGACTTGAAAC 1921 TTCCAGTGTGAGTTGACCCCATCATTTAAAAATAAAGTCCCCGGGTTCCTTAATGCCTCCTTCACTGGGCCTTCCTAGCA 2001 GGATAGAAAGTCCTTGCCCAGAGCAGGACCTGGCTGTCTTTTTTTTTTTTTTTTTTTTTTTCCCGAGACCAAGTTTCACT 2081 CTGTTGCCCAAGGTAGAGTGCAGTGGCGTGATCTCTGCTCATTGCAACTGCCGCCTCCCGGGTTCAAGCAATTCTCATGC 2161 ATCAGCCTCCCAAGTACCTGGGACTACAGGCGTGAGCTACCATGCCCGGCTAATTTTTGTATTTTTAGTAGAGATGGGGT 2241 TTCATTATGTTGGCCAGGCTGGTCTCGAACTCCTTACCTCAGGTGATCCACCCACCTTGGCCTCCCGAAGTGCTGGGATT 2321 ACAGGCATGAGCCACTGCGCCCGGCCATGGACCTGGCTGTCTTTATCATCCCCACAAACATTTTGAAACTGGAATATTTG 2401 TCTTCAGAAAATGGAAACAAGACTATAAATGATAAGCCCTGTCCCTAGCACCACCTCTCCTGTGTGTGGAATAGAGGCCC 2481 CTCGTGCTACCAACACTTACCCTGTGTTTAAAAAGATCTTGTACCAAGCCAACGGCGTTCCTGGCTCTCCTGCCCACAGG 2561 ATGAACATTTTCGGCTTCCTTAGGAGTTTTGCCCTACCGTATTCCAAAGCGTGTGCTGGTTTCTCATATTGTCTGTAGGC 2641 TCACTCAGCCCGCAGTTTATGTGTGTGCTTTTTTCTATGAAAAATGATGTATTTTGCTACTTCCTGTGTACAAAGTTTTA 2721 TTGTAAATGTTTTTTGTGCTTTGCATGAACAGGGGCCACGTTGTTGCAATTGTTTCAGTAGAACTGGTTTGATTTCTAAA 2801 ATGTTCCTGTAACATATCTTTTATGAACAAATCTGAACAATTTGTGAAATAAAACATTGAAAACCATCAAAAAAAAAAAA 2881 AAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | BT474 | |||||||||
Location of target site | 3'UTR | |||||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | |||||||||
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1395167. RNA binding protein: AGO. Condition:BT474 AGO HITS-CLIP Replicate 2
... - Pillai MM; Gillen AE; Yamamoto TM; Kline E; et al., 2014, Breast cancer research and treatment. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Pillai MM; Gillen AE; Yamamoto TM; Kline E; et al. - Breast cancer research and treatment, 2014
miRNAs regulate the expression of genes in both normal physiology and disease. While miRNAs have been demonstrated to play a pivotal role in aspects of cancer biology, these reports have generally focused on the regulation of single genes. Such single-gene approaches have significant limitations, relying on miRNA expression levels and heuristic predictions of mRNA-binding sites. This results in only circumstantial evidence of miRNA-target interaction and typically leads to large numbers of false positive predictions. Here, we used a genome-wide approach (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation, HITS-CLIP) to define direct miRNA-mRNA interactions in three breast cancer subtypes (estrogen receptor positive, Her2 amplified, and triple negative). Focusing on steroid receptor signaling, we identified two novel regulators of the ER pathway (miR-9-5p and miR-193a/b-3p), which together target multiple genes involved in ER signaling. Moreover, this approach enabled the definition of miR-9-5p as a global regulator of steroid receptor signaling in breast cancer. We show that miRNA targets and networks defined by HITS-CLIP under physiologic conditions are predictive of patient outcomes and provide global insight into miRNA regulation in breast cancer.
LinkOut: [PMID: 24906430]
|
CLIP-seq Support 1 for dataset GSM1395167 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | BT474 / BT474 AGO HITS-CLIP Replicate 2 |
Location of target site | ENST00000262424.5 | 3UTR | CGGGAGGCAGAGCUUGCAGUGAGCCAAGAUCACGCCACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24906430 / GSE57855 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
119 hsa-miR-4532 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT451366 | UQCR11 | ubiquinol-cytochrome c reductase, complex III subunit XI | 2 | 2 | ||||||||
MIRT451448 | ZNF556 | zinc finger protein 556 | 2 | 4 | ||||||||
MIRT458550 | CYP2B6 | cytochrome P450 family 2 subfamily B member 6 | 2 | 2 | ||||||||
MIRT460274 | SLC26A2 | solute carrier family 26 member 2 | 2 | 2 | ||||||||
MIRT460365 | TXNDC16 | thioredoxin domain containing 16 | 2 | 4 | ||||||||
MIRT460539 | TM4SF5 | transmembrane 4 L six family member 5 | 2 | 2 | ||||||||
MIRT463626 | YY1 | YY1 transcription factor | 2 | 2 | ||||||||
MIRT468524 | SERTAD2 | SERTA domain containing 2 | 2 | 4 | ||||||||
MIRT469966 | PTPRF | protein tyrosine phosphatase, receptor type F | 2 | 8 | ||||||||
MIRT470076 | PTGES2 | prostaglandin E synthase 2 | 2 | 2 | ||||||||
MIRT474926 | KCTD20 | potassium channel tetramerization domain containing 20 | 2 | 2 | ||||||||
MIRT479976 | CARD10 | caspase recruitment domain family member 10 | 2 | 2 | ||||||||
MIRT485533 | GPRIN1 | G protein regulated inducer of neurite outgrowth 1 | 2 | 2 | ||||||||
MIRT485939 | ECSIT | ECSIT signalling integrator | 2 | 4 | ||||||||
MIRT486421 | RXRA | retinoid X receptor alpha | 2 | 2 | ||||||||
MIRT487665 | HPCAL1 | hippocalcin like 1 | 2 | 4 | ||||||||
MIRT488113 | POU3F1 | POU class 3 homeobox 1 | 2 | 4 | ||||||||
MIRT490648 | FEM1A | fem-1 homolog A | 2 | 2 | ||||||||
MIRT491313 | LRFN1 | leucine rich repeat and fibronectin type III domain containing 1 | 2 | 2 | ||||||||
MIRT491345 | CPNE5 | copine 5 | 2 | 2 | ||||||||
MIRT492688 | PHYHIP | phytanoyl-CoA 2-hydroxylase interacting protein | 2 | 2 | ||||||||
MIRT496879 | AHCYL2 | adenosylhomocysteinase like 2 | 2 | 2 | ||||||||
MIRT499243 | VAV3 | vav guanine nucleotide exchange factor 3 | 2 | 4 | ||||||||
MIRT508211 | SLC35E1 | solute carrier family 35 member E1 | 2 | 2 | ||||||||
MIRT532712 | SNRPD3 | small nuclear ribonucleoprotein D3 polypeptide | 2 | 2 | ||||||||
MIRT540807 | SLC35F5 | solute carrier family 35 member F5 | 2 | 2 | ||||||||
MIRT563529 | TAF8 | TATA-box binding protein associated factor 8 | 2 | 2 | ||||||||
MIRT607723 | LIMS1 | LIM zinc finger domain containing 1 | 2 | 2 | ||||||||
MIRT608089 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 | 2 | 2 | ||||||||
MIRT618519 | SELPLG | selectin P ligand | 2 | 2 | ||||||||
MIRT624702 | AQR | aquarius intron-binding spliceosomal factor | 2 | 2 | ||||||||
MIRT624769 | AKR1D1 | aldo-keto reductase family 1 member D1 | 2 | 2 | ||||||||
MIRT629974 | MRPL36 | mitochondrial ribosomal protein L36 | 2 | 2 | ||||||||
MIRT631355 | ZFP82 | ZFP82 zinc finger protein | 2 | 2 | ||||||||
MIRT631425 | CDNF | cerebral dopamine neurotrophic factor | 2 | 2 | ||||||||
MIRT631664 | NDUFV3 | NADH:ubiquinone oxidoreductase subunit V3 | 2 | 2 | ||||||||
MIRT631734 | SF3B1 | splicing factor 3b subunit 1 | 2 | 2 | ||||||||
MIRT632333 | TCEANC2 | transcription elongation factor A N-terminal and central domain containing 2 | 2 | 2 | ||||||||
MIRT632418 | SLC30A5 | solute carrier family 30 member 5 | 2 | 2 | ||||||||
MIRT632530 | PSMB2 | proteasome subunit beta 2 | 2 | 2 | ||||||||
MIRT633263 | LDLR | low density lipoprotein receptor | 2 | 2 | ||||||||
MIRT634326 | SLC43A2 | solute carrier family 43 member 2 | 2 | 2 | ||||||||
MIRT634752 | CRCP | CGRP receptor component | 2 | 2 | ||||||||
MIRT635411 | KIAA1614 | KIAA1614 | 2 | 2 | ||||||||
MIRT636280 | RFFL | ring finger and FYVE like domain containing E3 ubiquitin protein ligase | 2 | 2 | ||||||||
MIRT636290 | RAD51L3-RFFL | RAD51L3-RFFL readthrough | 2 | 2 | ||||||||
MIRT641737 | TXNL1 | thioredoxin like 1 | 2 | 2 | ||||||||
MIRT643527 | ERAP2 | endoplasmic reticulum aminopeptidase 2 | 2 | 2 | ||||||||
MIRT643554 | C11orf70 | chromosome 11 open reading frame 70 | 2 | 2 | ||||||||
MIRT647026 | NQO2 | N-ribosyldihydronicotinamide:quinone reductase 2 | 2 | 2 | ||||||||
MIRT647297 | RBM43 | RNA binding motif protein 43 | 2 | 2 | ||||||||
MIRT648123 | SEMA3E | semaphorin 3E | 2 | 4 | ||||||||
MIRT648610 | TPCN2 | two pore segment channel 2 | 2 | 2 | ||||||||
MIRT648716 | IL10RB | interleukin 10 receptor subunit beta | 2 | 2 | ||||||||
MIRT649424 | CDC14B | cell division cycle 14B | 2 | 2 | ||||||||
MIRT650028 | DSG3 | desmoglein 3 | 2 | 2 | ||||||||
MIRT650280 | TAS2R5 | taste 2 receptor member 5 | 2 | 2 | ||||||||
MIRT654238 | RNF115 | ring finger protein 115 | 2 | 2 | ||||||||
MIRT657031 | KCNJ6 | potassium voltage-gated channel subfamily J member 6 | 2 | 2 | ||||||||
MIRT658406 | FAM212B | family with sequence similarity 212 member B | 2 | 2 | ||||||||
MIRT661079 | FFAR2 | free fatty acid receptor 2 | 2 | 2 | ||||||||
MIRT661528 | NWD1 | NACHT and WD repeat domain containing 1 | 2 | 2 | ||||||||
MIRT661875 | PDLIM5 | PDZ and LIM domain 5 | 2 | 2 | ||||||||
MIRT662099 | ZNF419 | zinc finger protein 419 | 2 | 2 | ||||||||
MIRT663637 | HM13 | histocompatibility minor 13 | 2 | 2 | ||||||||
MIRT663702 | ABHD17B | abhydrolase domain containing 17B | 2 | 2 | ||||||||
MIRT663844 | TRIM72 | tripartite motif containing 72 | 2 | 2 | ||||||||
MIRT664768 | MESDC2 | mesoderm development LRP chaperone | 2 | 2 | ||||||||
MIRT665480 | VSTM4 | V-set and transmembrane domain containing 4 | 2 | 2 | ||||||||
MIRT666532 | RNF157 | ring finger protein 157 | 2 | 2 | ||||||||
MIRT668106 | GK5 | glycerol kinase 5 (putative) | 2 | 2 | ||||||||
MIRT669741 | HSPE1-MOB4 | HSPE1-MOB4 readthrough | 2 | 2 | ||||||||
MIRT671009 | MOB4 | MOB family member 4, phocein | 2 | 2 | ||||||||
MIRT671582 | SPIRE2 | spire type actin nucleation factor 2 | 2 | 2 | ||||||||
MIRT673260 | INO80 | INO80 complex subunit | 2 | 2 | ||||||||
MIRT673532 | ADRBK2 | G protein-coupled receptor kinase 3 | 2 | 2 | ||||||||
MIRT674713 | FAM73A | mitoguardin 1 | 2 | 2 | ||||||||
MIRT675204 | ZNF554 | zinc finger protein 554 | 2 | 2 | ||||||||
MIRT676487 | DSN1 | DSN1 homolog, MIS12 kinetochore complex component | 2 | 2 | ||||||||
MIRT676704 | GXYLT2 | glucoside xylosyltransferase 2 | 2 | 2 | ||||||||
MIRT676850 | ZMYM1 | zinc finger MYM-type containing 1 | 2 | 2 | ||||||||
MIRT676854 | RAB3B | RAB3B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT676914 | PHLDA3 | pleckstrin homology like domain family A member 3 | 2 | 2 | ||||||||
MIRT676999 | CYP20A1 | cytochrome P450 family 20 subfamily A member 1 | 2 | 2 | ||||||||
MIRT677187 | PDE12 | phosphodiesterase 12 | 2 | 2 | ||||||||
MIRT677472 | SLC7A11 | solute carrier family 7 member 11 | 2 | 2 | ||||||||
MIRT677561 | C19orf52 | translocase of inner mitochondrial membrane 29 | 2 | 2 | ||||||||
MIRT677778 | FKTN | fukutin | 2 | 2 | ||||||||
MIRT677895 | DCP1A | decapping mRNA 1A | 2 | 2 | ||||||||
MIRT677995 | GATC | glutamyl-tRNA amidotransferase subunit C | 2 | 2 | ||||||||
MIRT678238 | HMGB1 | high mobility group box 1 | 2 | 4 | ||||||||
MIRT678312 | MCM8 | minichromosome maintenance 8 homologous recombination repair factor | 2 | 2 | ||||||||
MIRT678436 | PDE4C | phosphodiesterase 4C | 2 | 2 | ||||||||
MIRT678479 | RNF222 | ring finger protein 222 | 2 | 2 | ||||||||
MIRT678590 | ZNF91 | zinc finger protein 91 | 2 | 2 | ||||||||
MIRT678862 | SLC7A14 | solute carrier family 7 member 14 | 2 | 2 | ||||||||
MIRT679240 | LRP10 | LDL receptor related protein 10 | 2 | 2 | ||||||||
MIRT679387 | WDR92 | WD repeat domain 92 | 2 | 2 | ||||||||
MIRT679500 | ZNF106 | zinc finger protein 106 | 2 | 2 | ||||||||
MIRT679580 | UGGT1 | UDP-glucose glycoprotein glucosyltransferase 1 | 2 | 2 | ||||||||
MIRT679826 | TMEM106B | transmembrane protein 106B | 2 | 2 | ||||||||
MIRT679859 | ZFP30 | ZFP30 zinc finger protein | 2 | 2 | ||||||||
MIRT680472 | C3 | complement C3 | 2 | 2 | ||||||||
MIRT683698 | LAX1 | lymphocyte transmembrane adaptor 1 | 2 | 2 | ||||||||
MIRT684267 | PRPF4 | pre-mRNA processing factor 4 | 2 | 2 | ||||||||
MIRT689404 | ZNF573 | zinc finger protein 573 | 2 | 2 | ||||||||
MIRT694756 | ZNF843 | zinc finger protein 843 | 2 | 2 | ||||||||
MIRT695955 | FANCM | Fanconi anemia complementation group M | 2 | 2 | ||||||||
MIRT696365 | EIF2S3 | eukaryotic translation initiation factor 2 subunit gamma | 2 | 2 | ||||||||
MIRT700681 | PPAP2B | phospholipid phosphatase 3 | 2 | 2 | ||||||||
MIRT701214 | ORAI2 | ORAI calcium release-activated calcium modulator 2 | 2 | 2 | ||||||||
MIRT702195 | LRRC58 | leucine rich repeat containing 58 | 2 | 2 | ||||||||
MIRT706799 | RAI1 | retinoic acid induced 1 | 2 | 2 | ||||||||
MIRT711086 | NEUROD2 | neuronal differentiation 2 | 2 | 2 | ||||||||
MIRT715997 | RGS12 | regulator of G protein signaling 12 | 2 | 2 | ||||||||
MIRT716399 | SEPT5 | septin 5 | 2 | 2 | ||||||||
MIRT718442 | RAB11B | RAB11B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT722159 | ARHGAP40 | Rho GTPase activating protein 40 | 2 | 2 | ||||||||
MIRT724960 | PTK6 | protein tyrosine kinase 6 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|